Clinical Trial Update: LBH589 in Combination With Capecitabine Plus/Minus (±) Lapatinib in Breast Cancer Patients [Phase 1]

View source ↗

Summary

This phase 1 study evaluated LBH589 (panobinostat) in combination with capecitabine, with or without lapatinib, in breast cancer; results were posted after the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• LBH589 (panobinostat)
• Lapatinib (Lapatinib)

Snippet

Sponsor: SCRI Development Innovations, LLC | Conditions: Breast Cancer | Phase 1 | Status: COMPLETED | Results posted: 2015-06-08